Skip to content

Novo Nordisk (NVO) Q1 2026 Earnings Boosted by Wegovy Demand

Published on · Source: finance.yahoo.com

Novo Nordisk (NVO) Q1 2026 Earnings Boosted by Wegovy Demand

AI Summary

Summarized by AI from the source below

Novo Nordisk (NVO) reported first-quarter revenue of 96.82 billion kroner, a 24% increase year-over-year, largely driven by sales of its Wegovy weight loss pill, which generated 2.26 billion kroner ($353.6 million) from 1.3 million prescriptions. The drugmaker has raised its full-year guidance, now projecting adjusted sales and operating profit to decline between 4% and 12% in constant-currency terms, improving from prior estimates. The CEO noted that Wegovy captures 65% of new U.S. prescriptions in its category. Despite prior challenges, the earnings report indicates a recovery and better growth prospects ahead.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.

Share:

Get the weekly market brief

One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.

Get stories like this as they break

Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.